The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Other Barks and Bites for Friday, May 17: Senate AI Working Group Releases AI Policy Roadmap; Voice Actors Accuse AI Company of Stealing Their Voices; USPTO Accidentally Publishes Patent Application Titles
- MLC Expands Blanket License Enforcement Campaign With Lawsuit Against Spotify
- CAFC Dismisses Bid for PREP Act Protection Due to Lack of Jurisdiction Under Collateral Order Doctrine
- Chestek Takes Challenge of USPTO Domicile Address Rule for Trademark Applicants to High Court
- Why IP Rights Expire and Why They Must Be Strong While They Last